Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53

Clinical Cancer Research

Volumn 9, Issue 9, 2003, Pages 3492-3502

  Keshelava, Nino ^a   Tsao Wei, Denice ^b   Reynolds, C Patrick ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PROTEIN P53; TOPOTECAN;

ARTICLE; CANCER CELL CULTURE; CELL KILLING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; WART VIRUS;

ACRIDINES; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL LINE, TUMOR; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENES, P53; HUMANS; MICROSCOPY, FLUORESCENCE; NEUROBLASTOMA; OXYGEN; PYRAZOLES; TIME FACTORS;

EID: 0041833667     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., Gerbing, R. B., and Reynolds, C. P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med., 341: 1165-1173, 1999.
2. Keshelava, N., Seeger, R. C., Groshen, S., and Reynolds, C. P. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res., 58: 5396-5405, 1998.
3. Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J., and Reynolds, C. P. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res., 61: 6185-6193, 2001.
4. LoRusso, P., Wozniak, A. J., Polin, L., Capps, D., Leopold, W. R., Werbel, L. M., Biernat, L., Dan, M. E., and Corbett, T. H. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res., 50: 4900-4905, 1990.
5. Jackson, R. C., Sebolt, J. S., Shillis, J. L., and Leopold, W. R. The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Investig., 8: 39-47, 1990.
6. Sebolt, J. S., Scavone, S. V., Pinter, C. D., Hamelehle, K. L., Von Hoff, D. D., and Jackson, R. C. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res., 47: 4299-4304, 1987.
7. Sebolt, J., Havlick, M., Hamelehle, K., Nelson, J., Leopold, W., and Jackson, R. Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother. Pharmacol., 24: 219-224, 1989.
8. Cole, S. P. Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother. Pharmacol., 26: 250-256, 1990.
9. Adjei, A. A., Charron, M., Rowinsky, E. K., Svingen, P. A., Miller, J., Reid, J. M., Sebolt-Leopold, J., Ames, M. M., and Kaufmann, S. H. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin. Cancer Res., 4: 683-691, 1998.
10. LoRusso, P., Foster, B. J., Poplin, E., McCormick, J., Kraut, M., Flaherty, L., Heilbrun, L. K., Valdivieso, M., and Baker, L. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin. Cancer Res., 1: 1487-1493, 1995.
11. Grem, J. L., Harold, N., Keith, B., Chen, A. P., Kao, V., Takimoto, C. H., Hamilton, J. M., Pang, J., Pace, M., Jasser, G. B., Quinn, M. G., and Monahan, B. P. A Phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients. Clin. Cancer Res., 8: 2149-2156, 2002.
12. Berg, S. L., Blaney, S. M., Adamson, P. C., O'Brien, M., Poplack, D. G., Arndt, C., Blatt, J., and Balis, F. M. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J. Clin. Oncol., 16: 181-186, 1998.
13. Rowinsky, E. K., Noe, D. A., Grochow, L. B., Sartorious, S. E., Bowling, M. K., Chen, T. L., Lubejko, B. G., Kaufmann, S. H., and Donehower, R. C. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J. Clin. Oncol., 13: 1975-1984, 1995.
14. Kuebler, J. P., King, G. W., Triozzi, P., Moore, T., and Kraut, E. H. Phase II study of pyrazoloacridine in metastatic renal cell carcinoma. Investig. New Drugs, 19: 327-328, 2001.
15. Plaxe, S. C., Blessing, J. A., Morgan, M. A., and Carlson, J. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. Am. J. Clin. Oncol., 25: 45-47, 2002.
16. Plaxe, S. C., Blessing, J. A., Husseinzadeh, N., Webster, K. D., Rader, J. S., and Dunton, C. J. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol. Oncol., 84: 241-244, 2002.
17. Plaxe, S. C., Blessing, J. A., Bookman, M. A., and Creasman, W. T. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol., 84: 32-35, 2002.
18. Plaxe, S. C., Blessing, J. A., Lucci, J. A., and Hurteau, J. A. A Phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Investig. New Drugs, 19: 77-80, 2001.
19. Berg, S. L., Blaney, S. M., Sullivan, J., Bernstein, M., Dubowy, R., and Harris, M. B. Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol., 22: 506-509, 2000.
20. Pelley, R., Ganapathi, R., Wood, L., Rybicki, L., McLain, D., Budd, G. T., Peereboom, D., Olencki, T., and Bukowski, R. M. A Phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer. Cancer Chemother. Pharmacol., 46: 251-254, 2000.
21. Vuky, J., McCaffrey, J., Ginsberg, M., Mariani, T., Bajorin, D. F., Bosl, G. J., and Motzer, R. J. Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Investig. New Drugs, 18: 265-267, 2000.
22. Dodd, P. M., McCaffrey, J. A., Mazumdar, M., Icasiano, E., Higgins, G., Herr, H., and Bajorin, D. F. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. Investig. New Drugs, 18: 247-251, 2000.
23. Berg, W. J., McCaffrey, J., Schwartz, L. H., Mariani, T., Mazumdar, M., and Motzer, R. J. A Phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. Investig. New Drugs, 16: 337-340, 1998.
24. Small, E. J., Fippin, L. J., and Whisenant, S. P. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Investig., 16: 456-461, 1998.
25. Zalupski, M. M., Shields, A. F., Philip, P. A., Kraut, M., LoRusso, P., Heilbrun, L. K., and Vaitkevicius, V. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Investig. New Drugs, 16: 93-96, 1998.
26. Zalupski, M. M., Philip, P. A., LoRusso, P., and Shields, A. F. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemother. Pharmacol., 40: 225-227, 1997.
27. Keshelava, N., Groshen, S., and Reynolds, C. P. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother. Pharmacol., 45: 1-8, 2000.
28. Anderson, C. P., Seeger, R. C., Satake, N., Meek, W. E., Keshelava, N., Bailey, H. H., Monforte-Munoz, H. L., and Reynolds, C. P. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in melphalan-resistant neuroblastoma cell line. J. Pediatr. Hematol. Oncol., 23: 500-505, 2001.
29. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90: 809-819, 1997.
30. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75: 495-505, 1993.
31. Proffitt, R. T., Tran, J. V., and Reynolds, C. P. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry, 24: 204-213, 1996.
32. Maurer, B. J., Melton, L., Billups, C., Cabot, M. C., and Reynolds, C. P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. (Bethesda), 92: 1897-1909, 2000.
33. Chou, J., and Chou, T. Multiple drug-effect analysis (program B). In: J. Chou and T. Chou (eds.), Dose-Effect Analysis with Microcomputers, pp. 19-64. New York: Memorial Sloan-Kettering Cancer Center, 1987.
34. Snedecor, G. W., Cochran, W. G. Statistical Methods. 6th Edition, pp. 271-275, Ames: The Iowa State University Press, 1967.
35. Goto, H., Keshelava, N., Matthay, K. K., Lukens, J. N., Gerbing, R. B., Stram, D. O., Seeger, R. C., and Reynolds, C. P. Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors. Med. Pediatr. Oncol., 35: 619-622, 2000.
36. Keshelava, N., Seeger, R. C., and Reynolds, C. P. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. Eur. J. Cancer, 33: 2002-2006, 1997.
37. Keshelava, N., Zuo, J. J., Waidyaratne, N. S., Triche, T. J., and Reynolds, C. P. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med. Pediatr. Oncol., 35: 563-568, 2000.
38. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
39. Yonish-Rouach, E., Deguin, V., Zaitchouk, T., Breugnot, C., Mishal, Z., Jenkins, J. R., and May, E. Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene, 11: 2197-2205, 1995.
40. Grem, J. L., Politi, P. M., Berg, S. L., Benchekroun, N. M., Patel, M., Balis, F. M., Sinha, B. K., Dahut, W., and Allegra, C. J. Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. Biochem. Pharmacol., 51: 1649-1659, 1996.